The AI system can detect a larger number of high-risk patients across France, Germany, Italy, Spain, and the UK by 2030.

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.

Owkin Inc. partnered with Astrazeneca plc to develop an artificial intelligence (AI)-powered tool to pre-screen for germline BRCA mutations (gBRCAm) in breast cancer directly from digitized pathology ...

Inn from the Cold will be announcing a major expansion of services aimed at providing enhanced support to vulnerable Calgary families, to now include expectant mothers. Full details will be revealed ...

Alfa Laval will release third quarter earnings on 24 October at 07:30 am CET. The conference call will start at 09:00 am CET. The conference call is hosted by Alfa Laval's President and CEO Tom Erixon ...

The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.

SAN DIEGO — The novel antibody-drug conjugate tusamitamab ravtansine (tusa rav, Sanofi) did not demonstrate greater efficacy than docetaxel in treating advanced nonsquamous non–small cell lung ...

AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novartis, and Servier all agreed to share drug discovery data – but not with each other directly, nor with Owkin. Instead ...

(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient ...